Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gumokimab, an antibody targeting IL-17A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Gefurulimab, an antibody targeting C5 × Albumin.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Danburstotug, an antibody targeting PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Crefmirlimab, an antibody targeting CD8A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Anselamimab, an antibody targeting Light Chain Amyloid Fibrils.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zigakibart, an antibody targeting APRIL.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vilamakitug, an antibody targeting IL-1alpha.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Veligrotug, an antibody targeting IGF-1R.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vamikibart, an antibody targeting IL6.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Umesolerbart, an antibody targeting Bet v 1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tulisokibart, an antibody targeting TL1A.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Suvemcitug, an antibody targeting VEGF-A.